Healx, a leading UK artificial intelligence-powered biotech company, continues to reshape drug discovery for rare diseases in 2026, leveraging advanced machine learning to accelerate treatments for conditions that affect millions but often lack approved therapies.

Patients Know Best has collaborated with Heartfelt Technologies to automate and accelerate clinical trial recruitment, by taking a digital-first approach to patients.

A University of Bristol spin-out which has developed an innovative temperature-responsive coating for greenhouses and buildings has been awarded its first UK patent.

Bioprocessing leader to drive continued commercial development and international expansion.

Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis.

ZeroRISC has delivered a production-grade, open-source cryptographic hardware and software stack designed to secure systems in a post-quantum computing era, stemming from a multi-year collaboration with the Max Planck Institute for Security and Privacy and the Institute of Information Science at Academia Sinica.

Abselion, a life sciences tech company anchored in Cambridge UK and focused on simplifying biomolecule quantification, has established a US subsidiary at The Engine in Cambridge, MA.

CamGene Therapeutics, based in Hauxton, has won the HCR Law Impact55 title. The company uses biotechnology to develop medicines that aim to treat hearing loss rather than simply manage it.

Eco-Inject, a Cambridge Science Park medical device company reinventing the autoinjector, has completed a £5.2 million equity raise led by British investment syndicate, Adjuvo and is targeting a significant slice of a huge international market.

Axol Bioscience, a life science business headquartered in Edinburgh but with facilities at Babraham Research Campus in Cambridge, has made a key acquisition not long after raising $2.8 million.

London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.

London-based Orthofuse has secured a £2.2 million seed round to reshape the way complex orthopaedic procedures are performed. The round was led by a group of angel investors, with additional participation from ACF Investors, Cambridge Angels, and Empirical Ventures.